Cargando…
Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430778/ https://www.ncbi.nlm.nih.gov/pubmed/37593095 http://dx.doi.org/10.3389/fonc.2023.1046266 |
_version_ | 1785091044584456192 |
---|---|
author | Qi, Rongbin Xu, Hailing Fu, Xinyu Yu, Yingying Lv, Dongqing Li, Yujing He, Susu |
author_facet | Qi, Rongbin Xu, Hailing Fu, Xinyu Yu, Yingying Lv, Dongqing Li, Yujing He, Susu |
author_sort | Qi, Rongbin |
collection | PubMed |
description | Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus, rash, and infrequently, eruptive keratoacanthoma. Here, we report a case of a 67-year-old woman who developed eruptive keratoacanthoma of the skin 6 weeks after beginning treatment with a bispecific antibody (PM8001), targeting both programmed cell death receptor 1 and transforming growth factor β, as well as type I diabetes mellitus–induced ketoacidosis after 13 weeks. The type I diabetes appeared to stabilize after insulin treatment, and the keratoacanthoma gradually resolved after drug discontinuation. This case report describes a case of the effects of PM8001 immunotherapy on the endocrine glands and skin, together with a review of the relevant literature, and summarizes the different clinical characteristics of rare immune-related adverse events resulting from PM8001 immunotherapy to provide a reference for their early detection, diagnosis, and treatment. |
format | Online Article Text |
id | pubmed-10430778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104307782023-08-17 Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 Qi, Rongbin Xu, Hailing Fu, Xinyu Yu, Yingying Lv, Dongqing Li, Yujing He, Susu Front Oncol Oncology Immune-related adverse reactions primarily involve the skin and the endocrine, digestive, and respiratory systems. In the endocrine system, these adverse effects mainly include hypophysitis, thyroiditis, hypoadrenalism, and rarely, diabetes mellitus. The most common symptoms in the skin are pruritus, rash, and infrequently, eruptive keratoacanthoma. Here, we report a case of a 67-year-old woman who developed eruptive keratoacanthoma of the skin 6 weeks after beginning treatment with a bispecific antibody (PM8001), targeting both programmed cell death receptor 1 and transforming growth factor β, as well as type I diabetes mellitus–induced ketoacidosis after 13 weeks. The type I diabetes appeared to stabilize after insulin treatment, and the keratoacanthoma gradually resolved after drug discontinuation. This case report describes a case of the effects of PM8001 immunotherapy on the endocrine glands and skin, together with a review of the relevant literature, and summarizes the different clinical characteristics of rare immune-related adverse events resulting from PM8001 immunotherapy to provide a reference for their early detection, diagnosis, and treatment. Frontiers Media S.A. 2023-08-01 /pmc/articles/PMC10430778/ /pubmed/37593095 http://dx.doi.org/10.3389/fonc.2023.1046266 Text en Copyright © 2023 Qi, Xu, Fu, Yu, Lv, Li and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qi, Rongbin Xu, Hailing Fu, Xinyu Yu, Yingying Lv, Dongqing Li, Yujing He, Susu Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title | Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title_full | Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title_fullStr | Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title_full_unstemmed | Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title_short | Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1 |
title_sort | case report: keratoacanthoma and type i diabetes secondary to treatment with pm8001, a bifunctional fusion protein targeting tgf-β and pd-l1 |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430778/ https://www.ncbi.nlm.nih.gov/pubmed/37593095 http://dx.doi.org/10.3389/fonc.2023.1046266 |
work_keys_str_mv | AT qirongbin casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT xuhailing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT fuxinyu casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT yuyingying casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT lvdongqing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT liyujing casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 AT hesusu casereportkeratoacanthomaandtypeidiabetessecondarytotreatmentwithpm8001abifunctionalfusionproteintargetingtgfbandpdl1 |